Sequential treatment with antiblastic drugs allow to utilise different agents at the optimal dosage avoiding the addition of side effects. Furthermore this modality of treatment may override the phenomena of pharmaco-resistance. We have designed a clinical trial to explore the efficacy and tolerability of the following sequential schedule: Cisplatin at a dose of 80 mg/m2 on day 1 and vinorelbin 25 mg/m2 on day 1-8 every 3 weeks were administered. After three courses of the above schedule the patients have been re-staged. Patients with CR, PR or SD have than received 3 courses of docetaxel 75 mg/m2 on day 1 every 3 weeks, whilst progressive diseases patients discontinued the study. 53 pts with unresectable NSCLC have been enrolled. 43 males, 10 females; mean age 56; stage III B: 20 (38%), stage IV: 33 (62%); PS 1: 32, PS 2: 21; adenocarcinoma: 19 (35%), squamous: 12 (22,6%); NSCLC: 22 (41,5%). The sequential treatment cisplatin/vinorelbin followed by docetaxel demonstrates, in our study, good activity (41,6%) with satisfactory toxicity and may represents a feasible alternative for treatment of advanced/metastatic NSCLC.
La chemioterapia sequenziale nel trattamento del cancro del polmone non a piccole cellule (NSCLC) in operabile
BIANCO, Andrea
2006
Abstract
Sequential treatment with antiblastic drugs allow to utilise different agents at the optimal dosage avoiding the addition of side effects. Furthermore this modality of treatment may override the phenomena of pharmaco-resistance. We have designed a clinical trial to explore the efficacy and tolerability of the following sequential schedule: Cisplatin at a dose of 80 mg/m2 on day 1 and vinorelbin 25 mg/m2 on day 1-8 every 3 weeks were administered. After three courses of the above schedule the patients have been re-staged. Patients with CR, PR or SD have than received 3 courses of docetaxel 75 mg/m2 on day 1 every 3 weeks, whilst progressive diseases patients discontinued the study. 53 pts with unresectable NSCLC have been enrolled. 43 males, 10 females; mean age 56; stage III B: 20 (38%), stage IV: 33 (62%); PS 1: 32, PS 2: 21; adenocarcinoma: 19 (35%), squamous: 12 (22,6%); NSCLC: 22 (41,5%). The sequential treatment cisplatin/vinorelbin followed by docetaxel demonstrates, in our study, good activity (41,6%) with satisfactory toxicity and may represents a feasible alternative for treatment of advanced/metastatic NSCLC.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
